A cartoon-style illustration of a small glass bottle labeled 'MAOIs' with a cute, smiling face and rosy cheeks, featuring a star-shaped eye and a winking eye.

MAOIs

MAOIs (monoamine oxidase inhibitors) are a class of antidepressant medications that work by blocking the breakdown of neurotransmitters such as serotonin, dopamine, and norepinephrine. They are typically used for treatment-resistant depression or atypical depression when other medications have failed. Common examples include phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), and selegiline. MAOIs require dietary and medication restrictions because of potential interactions that can cause serious side effects.

  • This page summarizes anecdotal reports and community observations, not medical evidence. Reports may be incomplete, biased or inaccurate and are not medical advice or recommendations. “Risk” here refers to how frequently severe or prolonged symptom worsening is reported, not to proven causation or population-wide probability. Individual responses vary widely, and absence of issues in some users does not rule out significant reactions in others.

  • Within PFS/PSSD/PAS communities, MAOIs are discussed in relation to their potential interactions with monoamine signaling pathways. MAOIs (monoamine oxidase inhibitors) work by inhibiting monoamine oxidase enzymes (MAO-A and/or MAO-B), which normally break down neurotransmitters such as serotonin, norepinephrine, and dopamine—so monoamine signaling increases. Phenelzine also has an additional mechanism discussed in the literature—GABA-transaminase inhibition—which can increase brain GABA and may contribute to anxiolytic effects in some users. These mechanisms may interact with pathways involving monoamine signaling, GABA modulation, or neurosteroid balance that are often discussed in relation to PFS / PSSD / PAS. (ncbi) (mayoclinic) (pubmed) (ncbi)

  • Reports of Variable Outcomes (for PFS/PSSD/PAS):

    Among individuals with established PFS, PSSD, or PAS, MAOIs are discussed less frequently than SSRIs or SNRIs, but are still described in community reports as potentially destabilizing for some users. Anecdotes describe symptom worsening involving anxiety, sleep disruption, emotional blunting, and anhedonia, with some individuals reporting both acute exacerbations and longer-lasting declines in baseline after use. At the same time, there are reports of MAOIs temporarily alleviating certain symptoms—such as mood, motivation, or anxiety—leading some to describe their effects as a short-term “band-aid” rather than a durable improvement. Overall, MAOIs are approached with moderate caution within the community, as experiences appear highly variable and unpredictable in the absence of controlled data.

    For individuals without these conditions, MAOIs are effective for some people but require careful dietary and medication interaction management.

    Evidence basis: Established pharmacology and clinical safety guidance for MAOIs; anecdotal reports (online forums, self-reports); no controlled studies examining PFS/PSSD/PAS-specific outcomes.

  • Crash / Baseline Drop (Reported)

    Anecdote 1 Link

Public comments reflect individual experiences and opinions. They are not medical advice and may not be accurate or representative.

Return To Home